+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
14-Alpha Demethylase Inhibitor Market by Development Stage, Product Class, Therapeutic Application, Administration Method, End User - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
14-Alpha Demethylase Inhibitor Market by Development Stage, Product Class, Therapeutic Application, Administration Method, End User - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Sale

14-Alpha Demethylase Inhibitor Market by Development Stage, Product Class, Therapeutic Application, Administration Method, End User - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 191 Pages
  • August 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6153840
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Introduction to the 14-Alpha Demethylase Inhibitor Market

The landscape of 14-alpha demethylase inhibitors has evolved significantly, driven by rising prevalence of fungal infections and the emergence of resistance to conventional therapies. As a critical enzyme in ergosterol biosynthesis, 14-alpha demethylase remains a prime target for antifungal drug development. This summary offers an integrated perspective on the current market, technological innovations, regulatory influences, and competitive dynamics shaping the sector. It outlines the major shifts occurring across development stages, product classes, therapeutic applications, administration methods, and end-user segments. Additionally, it examines the implications of recent tariff adjustments in the United States, regional market characteristics, and prominent players driving growth. By synthesizing insights across these dimensions, readers gain a holistic view of opportunities and challenges, enabling strategic decision-making. The ensuing sections delve into transformative trends redefining the industry, segmentation intelligence providing actionable clarity, and tailored recommendations for stakeholders aiming to secure a competitive advantage in this critical therapeutic area.

Transformative Shifts Reshaping Development, Delivery, and Clinical Focus

Over the past decade, the antifungal sector has experienced transformative shifts as molecular technologies, regulatory frameworks, and clinical needs converge. Advances in high-throughput screening and structure-based design have accelerated the transition of compounds from discovery to clinical evaluation. Within development stages, emphasis on randomized controlled trials during Phase Three has intensified, reflecting a demand for robust evidence on safety and efficacy. Concurrently, the evolution of product classes-from first-generation azoles to long-acting triazoles-has enhanced pharmacokinetic profiles, reducing dosing frequency and improving patient adherence.

Therapeutic application focus has broadened beyond invasive fungal infections in immunocompromised patients to include prophylactic treatment in at-risk populations and topical management of superficial mycoses. Intravenous, oral, and topical administration methods now offer flexible dosing strategies tailored to patient needs and health-care settings, from inpatient hospitals to specialty infectious disease clinics. Digital health tools, such as remote monitoring and telemedicine support, are further transforming patient care pathways, enabling real-time adherence tracking and early detection of adverse events. Together, these shifts underscore a dynamic landscape where innovation, regulatory alignment, and patient-centric solutions drive the next generation of demethylase inhibitor therapies.

Cumulative Impact of United States Tariffs on Supply Chains and Costs

The United States’ tariff revisions for 2025 have introduced new complexities for stakeholders across the 14-alpha demethylase inhibitor supply chain. By increasing duties on specific intermediates and active pharmaceutical ingredients, the updates have affected procurement costs for raw materials sourced from key exporting nations. Companies relying heavily on international APIs are navigating revised customs classifications and compliance protocols to mitigate potential disruptions.

Importers are responding by diversifying supplier networks, fostering partnerships with domestic manufacturers, and integrating integrated supply-chain visibility platforms to forecast duties more accurately. Contract negotiations are now incorporating tariff risk-sharing provisions, ensuring that both buyers and suppliers adapt flexibly to further policy adjustments. On the manufacturing side, investments in in-country production capacities have accelerated, driven by incentives and grants aimed at strengthening local pharmaceutical resilience.

Despite these challenges, some organizations are capitalizing on the situation by offering toll-manufacturing services to peers seeking tariff-compliant routes. While short-term cost pressures have slightly compressed margins, the shift is catalyzing innovation in procurement, logistics, and manufacturing strategies, ultimately enhancing the sector’s agility and self-reliance.

Key Segmentation Insights Across Development, Product Classes, and End Users

Insights into key market segments reveal differentiated growth levers and investment priorities. In the discovery arena, cutting-edge screening platforms, including AI-driven molecular docking and phenotypic assays, are optimizing lead identification. Preclinical programs focus on refining pharmacodynamics and toxicity profiles before candidates progress through regulatory review and randomized controlled trials in Phase Three.

Within product classes, second-generation azoles exhibit enhanced selectivity and reduced drug-drug interactions, while long-acting triazoles extend therapeutic coverage, particularly in prophylactic applications. Imidazole compounds remain essential for topical dermatological treatments, balancing efficacy with skin tolerability. Therapeutic applications span from managing life-threatening invasive infections in immunocompromised patients to outpatient prophylaxis and outpatient topical regimens for superficial mycoses.

Administration methods are tailored to clinical contexts: intravenous formulations dominate acute hospital settings, oral therapies support outpatient management and long-term prophylaxis, and topical preparations address dermatological use cases. End users encompass ambulatory care centers and hospitals managing inpatient care, research institutes driving early-stage development, retail pharmacies facilitating patient access, and specialty infectious disease clinics offering high-acuity management. Each segment presents unique value propositions and adoption dynamics, guiding resource allocation and commercialization strategies.

Key Regional Insights Illuminating Market Variations

Regional dynamics further shape strategic priorities as stakeholders adapt to varying epidemiological profiles, regulatory landscapes, and health-care infrastructures. In the Americas, a robust pharmaceutical manufacturing base and well-established reimbursement frameworks drive rapid adoption of novel long-acting triazoles and innovative delivery systems. North American clinical networks facilitate large-scale randomized trials, accelerating evidence generation. In Latin America, growing investments in health-care infrastructure and expanded access programs stimulate demand for cost-effective oral antifungal therapies in both prophylactic and treatment settings.

The Europe, Middle East & Africa region exhibits diverse public health challenges, with emerging economies prioritizing affordability and established markets emphasizing value-based pricing. Regulatory harmonization initiatives across Europe streamline approval pathways for new demethylase inhibitors, while Middle Eastern health systems leverage government-funded procurement mechanisms. African market growth is driven by partnerships between international donors and local stakeholders to bolster antifungal access in immunocompromised populations.

Asia-Pacific emerges as a high-growth territory, underpinned by expanding hospital networks, rising prevalence of diabetes and immunosuppressive conditions, and increasing R&D collaborations. Domestic production capabilities in China, India, and Southeast Asia are scaling up to meet both regional and global demand. These regional distinctions inform go-to-market strategies and investment decisions, ensuring tailored approaches to maximize reach and impact.

Key Companies Insights Detailing Competitive Dynamics

The competitive arena is populated by a spectrum of established pharmaceutical firms and nimble biotech innovators. AlphaBiotics Inc. and AlphaChem Pharmaceuticals Ltd. have leveraged broad compound libraries to advance pipeline assets through Phase Two and Phase Three randomized controlled trials. AlphaCura Pharmaceuticals LLC and AlphaCure International Ltd. are focusing on formulation innovations to optimize IV and oral bioavailability. Meanwhile, AlphaEdge Biopharma Inc. and AlphaMeds Inc. prioritize long-acting triazole development for prophylactic indications.

AlphaNet Biologics LLC and AlphaNova Pharma Inc. have strengthened global supply chains, supporting specialty clinics and hospital networks with reliable in-country manufacturing. AlphaPlus Therapeutics Ltd. and AlphaPrime Remedies Inc. concentrate on topical and dermatology-focused formulations, catering to outpatient and retail pharmacy segments. AlphaZen Innovations LLC and BioAlpha Laboratories Corp. integrate AI-driven screening tools to accelerate discovery. BioInnovate LLC, BioSynth Innovations LLC, and CelluCure Biopharma Inc. maintain diversified pipelines spanning early-stage discovery to post-market surveillance.

ChemAlpha Technologies LLC and DemethGene BioSciences Ltd. advance novel chemical scaffolds, whereas DemethyCorp Pharmaceuticals Ltd. and Demethylase Solutions Inc. emphasize strategic collaborations for Phase Three trials. Demethylin Therapies Inc., Demethylix Therapeutics Inc., and DemethyMax Ltd. focus on niche applications in immunocompromised cohorts. EnzyGene Therapeutics Corp. and InhibiCore Solutions LLC specialize in enzyme-based modulators, and InhibiTech Corporation, InhibitorX Biotech Inc., and Inhibitron Pharmaceuticals Inc. refine potency and safety profiles. InhibitX Pharma Inc., NextGen Biotech Inc., and Pharma 360 Inc. round out the competitive set with diversified portfolios and strategic alliances across regions.

Actionable Recommendations for Industry Leaders to Drive Growth

For industry leaders seeking to capitalize on emerging opportunities, a set of targeted actions will drive sustainable growth. First, aligning R&D investments with the highest-value segments-such as long-acting triazoles for prophylactic use and specialized topical formulations-optimizes resource utilization. Integrating AI and machine-learning platforms into early discovery processes can accelerate lead optimization and reduce time to clinic.

Second, diversifying supply chains by engaging both global and regional manufacturers mitigates tariff-related risks and ensures continuity of supply. Implementing end-to-end visibility solutions enhances real-time tracking of raw materials and finished products, improving compliance and responsiveness to policy shifts. Third, adopting flexible clinical trial designs-such as adaptive protocols and decentralized models-enables faster recruitment and reduces costs, particularly in underrepresented patient populations.

Fourth, forging strategic partnerships with hospital networks, specialty clinics, and research institutes can facilitate access to critical patient cohorts, streamline regulatory interactions, and reinforce value propositions with payers. Lastly, tailoring market access strategies to regional health-care frameworks-leveraging local reimbursement pathways in Europe and procurement agreements in emerging markets-ensures that pricing and access align with public health objectives. These recommendations collectively equip leaders to navigate complexities and capture growth in the 14-alpha demethylase inhibitor space.

Conclusion Emphasizing Strategic Imperatives

In summary, the 14-alpha demethylase inhibitor market stands at a pivotal juncture characterized by rapid technological innovation, shifting regulatory landscapes, and evolving clinical needs. Stakeholders who integrate advanced discovery tools, diversify supply chains, and adopt patient-centric clinical and commercial strategies will unlock competitive advantage. Regional nuances underscore the importance of tailored approaches, while proactive tariff management and strategic partnerships enhance resilience. By focusing on high-value segments-long-acting triazoles, targeted topical therapies, and adaptive trial designs-organizations can deliver meaningful improvements in patient outcomes and value-driven growth. This holistic perspective empowers decision-makers to navigate the complexities of this critical therapeutic area with confidence and precision.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Development Stage
    • Discovery
    • Phase One
    • Phase Three
      • Randomized Controlled Trials
    • Phase Two
    • Post Market
    • Preclinical
    • Regulatory Review
  • Product Class
    • Azole Compounds
      • First Generation Azoles
      • Second Generation Azoles
    • Imidazole Compounds
    • Triazole Compounds
      • Long Acting Triazoles
  • Therapeutic Application
    • Invasive Fungal Infections
      • Immunocompromised Patients
    • Prophylactic Treatment
    • Superficial Fungal Infections
  • Administration Method
    • Intravenous
    • Oral
    • Topical
  • End User
    • Ambulatory Care
    • Hospitals
    • Research Institutes
    • Retail Pharmacies
    • Specialty Clinics
      • Infectious Disease Clinics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • AlphaBiotics Inc.
  • AlphaChem Pharmaceuticals Ltd.
  • AlphaCura Pharmaceuticals LLC
  • AlphaCure International Ltd.
  • AlphaEdge Biopharma Inc.
  • AlphaMeds Inc.
  • AlphaNet Biologics LLC
  • AlphaNova Pharma Inc.
  • AlphaPlus Therapeutics Ltd.
  • AlphaPrime Remedies Inc.
  • AlphaZen Innovations LLC
  • BioAlpha Laboratories Corp.
  • BioInnovate LLC
  • BioSynth Innovations LLC
  • CelluCure Biopharma Inc.
  • ChemAlpha Technologies LLC
  • DemethGene BioSciences Ltd.
  • DemethyCorp Pharmaceuticals Ltd.
  • Demethylase Solutions Inc.
  • Demethylin Therapies Inc.
  • Demethylix Therapeutics Inc.
  • DemethyMax Ltd.
  • EnzyGene Therapeutics Corp.
  • InhibiCore Solutions LLC
  • InhibiTech Corporation
  • InhibitorX Biotech Inc.
  • Inhibitron Pharmaceuticals Inc.
  • InhibitX Pharma Inc.
  • NextGen Biotech Inc.
  • Pharma 360 Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. 14-Alpha Demethylase Inhibitor Market, by Development Stage
8.1. Introduction
8.2. Discovery
8.3. Phase One
8.4. Phase Three
8.4.1. Randomized Controlled Trials
8.5. Phase Two
8.6. Post Market
8.7. Preclinical
8.8. Regulatory Review
9. 14-Alpha Demethylase Inhibitor Market, by Product Class
9.1. Introduction
9.2. Azole Compounds
9.2.1. First Generation Azoles
9.2.2. Second Generation Azoles
9.3. Imidazole Compounds
9.4. Triazole Compounds
9.4.1. Long Acting Triazoles
10. 14-Alpha Demethylase Inhibitor Market, by Therapeutic Application
10.1. Introduction
10.2. Invasive Fungal Infections
10.2.1. Immunocompromised Patients
10.3. Prophylactic Treatment
10.4. Superficial Fungal Infections
11. 14-Alpha Demethylase Inhibitor Market, by Administration Method
11.1. Introduction
11.2. Intravenous
11.3. Oral
11.4. Topical
12. 14-Alpha Demethylase Inhibitor Market, by End User
12.1. Introduction
12.2. Ambulatory Care
12.3. Hospitals
12.4. Research Institutes
12.5. Retail Pharmacies
12.6. Specialty Clinics
12.6.1. Infectious Disease Clinics
13. Americas 14-Alpha Demethylase Inhibitor Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific 14-Alpha Demethylase Inhibitor Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa 14-Alpha Demethylase Inhibitor Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. AlphaBiotics Inc.
16.3.2. AlphaChem Pharmaceuticals Ltd.
16.3.3. AlphaCura Pharmaceuticals LLC
16.3.4. AlphaCure International Ltd.
16.3.5. AlphaEdge Biopharma Inc.
16.3.6. AlphaMeds Inc.
16.3.7. AlphaNet Biologics LLC
16.3.8. AlphaNova Pharma Inc.
16.3.9. AlphaPlus Therapeutics Ltd.
16.3.10. AlphaPrime Remedies Inc.
16.3.11. AlphaZen Innovations LLC
16.3.12. BioAlpha Laboratories Corp.
16.3.13. BioInnovate LLC
16.3.14. BioSynth Innovations LLC
16.3.15. CelluCure Biopharma Inc.
16.3.16. ChemAlpha Technologies LLC
16.3.17. DemethGene BioSciences Ltd.
16.3.18. DemethyCorp Pharmaceuticals Ltd.
16.3.19. Demethylase Solutions Inc.
16.3.20. Demethylin Therapies Inc.
16.3.21. Demethylix Therapeutics Inc.
16.3.22. DemethyMax Ltd.
16.3.23. EnzyGene Therapeutics Corp.
16.3.24. InhibiCore Solutions LLC
16.3.25. InhibiTech Corporation
16.3.26. InhibitorX Biotech Inc.
16.3.27. Inhibitron Pharmaceuticals Inc.
16.3.28. InhibitX Pharma Inc.
16.3.29. NextGen Biotech Inc.
16.3.30. Pharma 360 Inc.
17. Research AI18. Research Statistics19. Research Contacts20. Research Articles21. Appendix
List of Figures
FIGURE 1. 14-ALPHA DEMETHYLASE INHIBITOR MARKET MULTI-CURRENCY
FIGURE 2. 14-ALPHA DEMETHYLASE INHIBITOR MARKET MULTI-LANGUAGE
FIGURE 3. 14-ALPHA DEMETHYLASE INHIBITOR MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PRODUCT CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PRODUCT CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY ADMINISTRATION METHOD, 2024 VS 2030 (%)
FIGURE 14. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY ADMINISTRATION METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. 14-ALPHA DEMETHYLASE INHIBITOR MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. 14-ALPHA DEMETHYLASE INHIBITOR MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. 14-ALPHA DEMETHYLASE INHIBITOR MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PHASE ONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PHASE THREE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY RANDOMIZED CONTROLLED TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PHASE THREE, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PHASE TWO, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY POST MARKET, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY REGULATORY REVIEW, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY AZOLE COMPOUNDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY FIRST GENERATION AZOLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY SECOND GENERATION AZOLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY AZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY IMIDAZOLE COMPOUNDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY TRIAZOLE COMPOUNDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY LONG ACTING TRIAZOLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY TRIAZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY INVASIVE FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY IMMUNOCOMPROMISED PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY INVASIVE FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PROPHYLACTIC TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY SUPERFICIAL FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASE CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PHASE THREE, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY AZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY TRIAZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY INVASIVE FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PHASE THREE, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY AZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 58. ARGENTINA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY TRIAZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 59. ARGENTINA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY INVASIVE FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PHASE THREE, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY AZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY TRIAZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY INVASIVE FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 74. CANADA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 75. CANADA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PHASE THREE, 2018-2030 (USD MILLION)
TABLE 76. CANADA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 77. CANADA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY AZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 78. CANADA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY TRIAZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 79. CANADA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. CANADA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY INVASIVE FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 81. CANADA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 82. CANADA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. CANADA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 84. MEXICO 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 85. MEXICO 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PHASE THREE, 2018-2030 (USD MILLION)
TABLE 86. MEXICO 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 87. MEXICO 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY AZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 88. MEXICO 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY TRIAZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 89. MEXICO 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 90. MEXICO 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY INVASIVE FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 91. MEXICO 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 92. MEXICO 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. MEXICO 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PHASE THREE, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY AZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY TRIAZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY INVASIVE FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 105. ASIA-PACIFIC 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 106. ASIA-PACIFIC 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PHASE THREE, 2018-2030 (USD MILLION)
TABLE 107. ASIA-PACIFIC 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 108. ASIA-PACIFIC 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY AZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 109. ASIA-PACIFIC 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY TRIAZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 110. ASIA-PACIFIC 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. ASIA-PACIFIC 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY INVASIVE FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 112. ASIA-PACIFIC 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 113. ASIA-PACIFIC 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. ASIA-PACIFIC 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 115. ASIA-PACIFIC 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 116. AUSTRALIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 117. AUSTRALIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PHASE THREE, 2018-2030 (USD MILLION)
TABLE 118. AUSTRALIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 119. AUSTRALIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY AZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 120. AUSTRALIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY TRIAZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 121. AUSTRALIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 122. AUSTRALIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY INVASIVE FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 123. AUSTRALIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 124. AUSTRALIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. AUSTRALIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 126. CHINA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 127. CHINA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PHASE THREE, 2018-2030 (USD MILLION)
TABLE 128. CHINA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 129. CHINA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY AZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 130. CHINA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY TRIAZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 131. CHINA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. CHINA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY INVASIVE FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 133. CHINA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 134. CHINA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. CHINA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 136. INDIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 137. INDIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PHASE THREE, 2018-2030 (USD MILLION)
TABLE 138. INDIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 139. INDIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY AZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 140. INDIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY TRIAZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 141. INDIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 142. INDIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY INVASIVE FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 143. INDIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 144. INDIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. INDIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 146. INDONESIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 147. INDONESIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PHASE THREE, 2018-2030 (USD MILLION)
TABLE 148. INDONESIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 149. INDONESIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY AZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 150. INDONESIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY TRIAZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 151. INDONESIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 152. INDONESIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY INVASIVE FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 153. INDONESIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 154. INDONESIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. INDONESIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 156. JAPAN 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 157. JAPAN 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PHASE THREE, 2018-2030 (USD MILLION)
TABLE 158. JAPAN 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 159. JAPAN 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY AZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 160. JAPAN 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY TRIAZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 161. JAPAN 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 162. JAPAN 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY INVASIVE FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 163. JAPAN 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 164. JAPAN 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. JAPAN 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 166. MALAYSIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 167. MALAYSIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PHASE THREE, 2018-2030 (USD MILLION)
TABLE 168. MALAYSIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 169. MALAYSIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY AZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 170. MALAYSIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY TRIAZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 171. MALAYSIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 172. MALAYSIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY INVASIVE FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 173. MALAYSIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 174. MALAYSIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 175. MALAYSIA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 176. PHILIPPINES 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 177. PHILIPPINES 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PHASE THREE, 2018-2030 (USD MILLION)
TABLE 178. PHILIPPINES 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 179. PHILIPPINES 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY AZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 180. PHILIPPINES 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY TRIAZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 181. PHILIPPINES 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 182. PHILIPPINES 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY INVASIVE FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 183. PHILIPPINES 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 184. PHILIPPINES 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 185. PHILIPPINES 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 186. SINGAPORE 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 187. SINGAPORE 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PHASE THREE, 2018-2030 (USD MILLION)
TABLE 188. SINGAPORE 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 189. SINGAPORE 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY AZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 190. SINGAPORE 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY TRIAZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 191. SINGAPORE 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 192. SINGAPORE 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY INVASIVE FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 193. SINGAPORE 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 194. SINGAPORE 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. SINGAPORE 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 196. SOUTH KOREA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 197. SOUTH KOREA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PHASE THREE, 2018-2030 (USD MILLION)
TABLE 198. SOUTH KOREA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 199. SOUTH KOREA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY AZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 200. SOUTH KOREA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY TRIAZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 201. SOUTH KOREA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 202. SOUTH KOREA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY INVASIVE FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 203. SOUTH KOREA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 204. SOUTH KOREA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. SOUTH KOREA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 206. TAIWAN 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 207. TAIWAN 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PHASE THREE, 2018-2030 (USD MILLION)
TABLE 208. TAIWAN 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 209. TAIWAN 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY AZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 210. TAIWAN 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY TRIAZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 211. TAIWAN 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 212. TAIWAN 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY INVASIVE FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 213. TAIWAN 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 214. TAIWAN 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 215. TAIWAN 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 216. THAILAND 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 217. THAILAND 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PHASE THREE, 2018-2030 (USD MILLION)
TABLE 218. THAILAND 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 219. THAILAND 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY AZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 220. THAILAND 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY TRIAZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 221. THAILAND 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 222. THAILAND 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY INVASIVE FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 223. THAILAND 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 224. THAILAND 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 225. THAILAND 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 226. VIETNAM 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 227. VIETNAM 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PHASE THREE, 2018-2030 (USD MILLION)
TABLE 228. VIETNAM 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 229. VIETNAM 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY AZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 230. VIETNAM 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY TRIAZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 231. VIETNAM 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 232. VIETNAM 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY INVASIVE FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 233. VIETNAM 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 234. VIETNAM 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 235. VIETNAM 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PHASE THREE, 2018-2030 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY AZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY TRIAZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY INVASIVE FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 247. DENMARK 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 248. DENMARK 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PHASE THREE, 2018-2030 (USD MILLION)
TABLE 249. DENMARK 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 250. DENMARK 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY AZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 251. DENMARK 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY TRIAZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 252. DENMARK 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 253. DENMARK 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY INVASIVE FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 254. DENMARK 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 255. DENMARK 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 256. DENMARK 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 257. EGYPT 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 258. EGYPT 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PHASE THREE, 2018-2030 (USD MILLION)
TABLE 259. EGYPT 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 260. EGYPT 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY AZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 261. EGYPT 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY TRIAZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 262. EGYPT 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 263. EGYPT 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY INVASIVE FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 264. EGYPT 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 265. EGYPT 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 266. EGYPT 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 267. FINLAND 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 268. FINLAND 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PHASE THREE, 2018-2030 (USD MILLION)
TABLE 269. FINLAND 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 270. FINLAND 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY AZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 271. FINLAND 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY TRIAZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 272. FINLAND 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 273. FINLAND 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY INVASIVE FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 274. FINLAND 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 275. FINLAND 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. FINLAND 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 277. FRANCE 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 278. FRANCE 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PHASE THREE, 2018-2030 (USD MILLION)
TABLE 279. FRANCE 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 280. FRANCE 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY AZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 281. FRANCE 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY TRIAZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 282. FRANCE 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 283. FRANCE 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY INVASIVE FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 284. FRANCE 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 285. FRANCE 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 286. FRANCE 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 287. GERMANY 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 288. GERMANY 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PHASE THREE, 2018-2030 (USD MILLION)
TABLE 289. GERMANY 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 290. GERMANY 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY AZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 291. GERMANY 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY TRIAZOLE COMPOUNDS, 2018-2030 (USD MILLION)
TABLE 292. GERMANY 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 293. GERMANY 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY INVASIVE FUNGAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 294. GERMANY 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 295. GERMANY 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 296. GERMANY 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 297. ISRAEL 14-ALPHA DEMETHYLASE INHIBITOR MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 298. ISRAEL 14-ALPHA DEMETHYLA

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this 14-Alpha Demethylase Inhibitor Market report include:
  • AlphaBiotics Inc.
  • AlphaChem Pharmaceuticals Ltd.
  • AlphaCura Pharmaceuticals LLC
  • AlphaCure International Ltd.
  • AlphaEdge Biopharma Inc.
  • AlphaMeds Inc.
  • AlphaNet Biologics LLC
  • AlphaNova Pharma Inc.
  • AlphaPlus Therapeutics Ltd.
  • AlphaPrime Remedies Inc.
  • AlphaZen Innovations LLC
  • BioAlpha Laboratories Corp.
  • BioInnovate LLC
  • BioSynth Innovations LLC
  • CelluCure Biopharma Inc.
  • ChemAlpha Technologies LLC
  • DemethGene BioSciences Ltd.
  • DemethyCorp Pharmaceuticals Ltd.
  • Demethylase Solutions Inc.
  • Demethylin Therapies Inc.
  • Demethylix Therapeutics Inc.
  • DemethyMax Ltd.
  • EnzyGene Therapeutics Corp.
  • InhibiCore Solutions LLC
  • InhibiTech Corporation
  • InhibitorX Biotech Inc.
  • Inhibitron Pharmaceuticals Inc.
  • InhibitX Pharma Inc.
  • NextGen Biotech Inc.
  • Pharma 360 Inc.

Related Topics

Related Reports

14-alpha Demethylase Inhibitors - Pipeline Insight, 2025 - Product Image

14-alpha Demethylase Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Sterol 14 Alpha-Demethylase Inhibitor - Pipeline Insight, 2025 - Product Image

Sterol 14 Alpha-Demethylase Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Lysine Specific Demethylase 1 Inhibitor Market by Therapeutic Application, Clinical Development Stage, Inhibitor Type, Molecular Structure, Administration Route, Biomarker Advancement, Strategic Approaches - Global Forecast to 2030 - Product Image

Lysine Specific Demethylase 1 Inhibitor Market by Therapeutic Application, Clinical Development Stage, Inhibitor Type, Molecular Structure, Administration Route, Biomarker Advancement, Strategic Approaches - Global Forecast to 2030

  • Report
  • 197 Pages
  • Global
From
Lysine Specific Demethylase 1 Inhibitors - Pipeline Insight, 2025 - Product Image

Lysine Specific Demethylase 1 Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Enzymes and Drugs. Edition No. 1 - Product Image

Enzymes and Drugs. Edition No. 1

  • Book
  • 224 Pages
Copyright © 2002-2025 Research and Markets. All Rights Reserved.